Drug-Eluting Balloon Versus Drug-Eluting Stent for Complex Femoropopliteal Arterial Lesions
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trialsEuropean Heart Journal, 2012
- Classification and Clinical Impact of Restenosis After Femoropopliteal StentingJACC, 2012
- Long-term Outcomes and Risk Stratification of Patency Following Nitinol Stenting in the Femoropopliteal Segment: Retrospective Multicenter AnalysisJournal of Endovascular Therapy, 2011
- Paclitaxel-Eluting Stents Show Superiority to Balloon Angioplasty and Bare Metal Stents in Femoropopliteal DiseaseCirculation: Cardiovascular Interventions, 2011
- Statins are independently associated with reduced mortality in patients undergoing infrainguinal bypass graft surgery for critical limb ischemiaJournal of Vascular Surgery, 2008
- Intravascular drug release kinetics dictate arterial drug deposition, retention, and distributionJournal of Controlled Release, 2007
- Long-Segment SFA Stenting—The Dark Sides: In-Stent Restenosis, Clinical Deterioration, and Stent FracturesJournal of Endovascular Therapy, 2005
- Prevalence and clinical impact of stent fractures after femoropopliteal stentingJACC, 2005
- Peripheral Arterial Disease in People With DiabetesDiabetes Care, 2003
- Prospective Randomized Open Blinded End-point (PROBE) Study. A novel design for intervention trialsBlood Pressure, 1992